Project Grant K01DK143205
- This $2,971,227 federal Project Grant, awarded on September 4, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to investigate the role of fatty acids in regulating cellular metabolism and protein synthesis in the context of fasting, inflammation, and metabolic diseases. The research aims to uncover novel signaling pathways through which fatty...
- This federal Project Grant award of $147,486 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) will fund research to investigate the role of gut microbes in regulating interleukin-22 (IL-22) levels in the pancreas and the impact on pancreatic health and disease. The research aims to determine how gut microbe-induced IL-22 affects pancreatic gene expression and the underlying cellular mechanisms, as well as the beneficial and detrimental effects of this...
- This $551,696 Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the cannabinoid 1 receptor (CB1R) in age-associated metabolic dysfunction-associated steatotic liver disease (MASLD). The research project, led by Oklahoma State University, seeks to determine how hepatic CB1R contributes to the exacerbation of MASLD...
- This $647,290 federal Project Grant was awarded on July 1, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research conducted by the University of California, Los Angeles (UCLA) to study the interplay between brain oxytocin and CRF (corticotropin-releasing factor) systems in stress-related visceral analgesia versus hyperalgesia, and the...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $808,866 to Progenra Inc., a biotechnology firm located in Malvern, Pennsylvania. The funding supports research to evaluate novel small molecule compounds that activate the ubiquitin proteasome system (UPS) as potential therapeutics for treating acute and chronic pancreatitis. Key objectives include assessing...
- The University of California, Davis received a $126,480 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to conduct research on the role of the signaling protein 14-3-3-z in regulating the crosstalk between pancreatic islet cells. The research aims to define a new pathway regulating 14-3-3-z expression in beta cells and investigate how this impacts alpha cell function and glucose-stimulated insulin secretion. This project is expected...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $320,778 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Vermont & State Agricultural College. The project, titled "PACAP/PAC1R Signaling and CRH Intersections in Micturition Circuits: Effects of Stress and Injury/Inflammation," will investigate how changes in central micturition and peripheral sensory circuits due to...
- This federal Project Grant award of $726,140.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant aims to elucidate the neural circuits and cellular mechanisms underlying visceral pain processing in the spinal cord and brainstem, with the goal of advancing understanding and treatment of visceral pain conditions such as irritable bowel syndrome,...
- This federal Project Grant award in the amount of $1,428,186.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Massachusetts. The project aims to investigate the role of CYP4F enzymes in regulating N-acyl amino acid signaling in humans, which has implications for understanding the early...
- This federal Project Grant award, valued at $238,276, was provided by the National Institute of Neurological Disorders and Stroke under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding supports research at the University of California, Irvine to investigate the role of the enzyme N-acylethanolamine acid amidase (NAAA) in the development of hyperalgesic priming, a model for studying the transition from acute to chronic pain. The project aims to identify the receptor...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $169,388 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of California, Irvine (UCI). The purpose of this 5-year grant, awarded on September 9, 2025, is to explore the role of the enzyme fatty acid amide hydrolase (FAAH) and its regulation of endocannabinoid signaling as a novel, opiate-sparing therapeutic target for managing pain associated with acute pancreatitis. The research project aims to identify the receptor systems mediating the analgesic effects of FAAH inhibition, assess changes in FAAH expression and activity, and profile the cellular substrates involved in providing pain relief through this mechanism. The findings are expected to reveal the intricate mechanisms of FAAH-regulated signaling and its impact on pain management for this prevalent gastrointestinal disorder.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $169.4k | 9/9/25 |